Shanghai Baize Biotechnology

Shanghai Baize Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of next-generation CAR-T cell therapies, particularly for solid tumors. As the core research and development arm of the Shanghai Cell Therapy Group, the company utilizes its proprietary Baize platform to engineer immune cells that can better penetrate and survive within the immunosuppressive tumor microenvironment. Their lead programs focus on targeting Glypican-3 (GPC3) for liver cancer and Mesothelin (MSLN) for various solid malignancies, employing "armored" CAR-T technology to enhance therapeutic efficacy. The company integrates advanced gene editing, nanobody technology, and large-scale cell manufacturing to provide personalized immunotherapy solutions. Shanghai Baize Biotechnology is a key player in the Chinese cell therapy landscape, aiming to transition CAR-T treatments from liquid to solid cancers.